MacroGenics pulls plug on Vobra duo ADC after seeing Phase 2 Prostate cancer data

CAR-T Digest - August 2020

21 Mar 2025: MacroGenics pulls plug on Vobra duo ADC after seeing phase 2 prostate cancer data

MacroGenics decided to halt the development of Vobramitamab duocarmazine (Vobra duo) after reviewing Phase 2 prostate cancer trial data, which showed a median progression-free survival (PFS) of 9.5 to 10 months
The decision was based on the therapy’s safety, efficacy, and competitive landscape, leading the company to explore potential partnerships instead of further internal development
Despite dropping vobra duo, MacroGenics remains committed to targeting B7-H3, advancing an alternative ADC, MGC026, which is in Phase 1 trials for solid tumors
The company is also progressing with MGC028, another ADC targeting ADAM9, and lorigerlimab, a PD-1xCTLA-4 bispecific antibody in Phase 2 trials for prostate cancer
MacroGenics had $201.7 million in cash at the start of 2024, projected to sustain operations into the second half of 2026, as it continues advancing its clinical pipeline